Intellia Therapeutics vs. Omeros: Which emerging biotech stock is a better buy in 2026? The Motley Fool 4d Rare Diseases Pharma Biotechnology All sources
Why CRISPR Therapeutics stock has been on a roller-coaster ride this year The Motley Fool 7d CRISPR Biology Biotechnology All sources
Improving the gene editing toolbox Collection – Contribution Highlights Behavioural and Social Sciences at Nature Research 14:57 Tue, 16 Jun Genetics Biology Biotech All sources
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy Pharmaceutical Technology 2d FDA Pharma Biotechnology All sources
East Yorkshire dad saves lives of his two young daughters by donating stem cells after rare genetic diagnosis Hull Live 3d Stem Cells East Yorkshire England All sources
Scientists just found that brain cells routinely shatter their own DNA while building the brain — And repair it within 24 hours Medical Daily 2d Neuroscience DNA Nature All sources
Why CRISPR Therapeutics stock has been on a roller-coaster ride this year The Motley Fool 7d CRISPR Therapeutics CRISPR/Gene Editing Biotechnology All sources
